Mahlabot Gad: Weiler, Strauss, and Whether the Plant-Based Engine Arrives With a Revenue Hole

The main article argued that Gad's 2026 test no longer sits only in the 2025 earnings line, but in whether the company can execute Timorim and Weiler at the same time without losing control of profitability. This follow-up isolates the Weiler thread: what exactly Gad is buying, how the deal economics are built, and why the plant-based growth engine already arrives with a visible revenue gap.

On paper, this is an easy deal to like. Gad is supposed to pay about NIS 46 million for 51% of Weiler, based on an enterprise value of NIS 95 million before net-financial-debt and normalized-working-capital adjustments. In 2024 Weiler posted NIS 59.9 million of revenue, NIS 11.6 million of EBITDA, NIS 12.6 million of adjusted EBITDA, and NIS 6.8 million of net profit. The agreement also includes a price-adjustment mechanism if 2025 or 2026 EBITDA misses target, and the future stages are already written into the structure through a Gad call option and a sellers' put option.

But the detail that changes the read sits deeper in the filing. Twenty-one percent of Weiler's sales come from dairy substitutes, and the bulk of that activity is contract manufacturing of Alpro products for Strauss. That activity is expected to end over the coming year as Strauss completes its own plant and moves into self-production. So Gad is not buying a plant-based engine already running on a clean base. It is buying platform, line capacity, know-how, and speed to market, while at the same time inheriting a replacement task.

That is the difference between a strategically sensible deal and a clean deal. Weiler may be exactly what Gad needs to enter tofu and dairy substitutes in a meaningful way. But the package coming in is not a set of stable, fully protected revenues. It is a platform where a meaningful slice of the most relevant revenue is already known to be in runoff.

Three points matter right away:

• Weiler gives Gad a real operating platform, not a concept. It has a 2,600 square meter plant in Netivot, operates 6 days a week, employs 66 people, produces about 12 thousand tons out of 20 thousand tons of potential capacity, and includes a dairy-substitutes line running at low utilization.
• The deal is not priced blind. The agreement includes a price-adjustment mechanism if Weiler misses EBITDA targets of NIS 13.5 million in 2025 and NIS 14.5 million in 2026, and the largest shortfall is supposed to come back to Gad out of the first net dividends flowing to the sellers.
• The March 18, 2026 competition-authority approval removed one of the main closing conditions, but even after that approval the parties were still continuing to satisfy the remaining conditions precedent. The story advanced, but it did not close.

Weiler Brings Gad A Platform, Not Protected Revenue

The positive side of the story is fully real. Weiler is not a pre-revenue experiment. It is a private company that showed growth in 2024 both on the top line and in profit. Revenue rose to NIS 59.9 million from NIS 52.9 million in 2023, gross profit rose to NIS 25.2 million from NIS 18.2 million, operating profit almost doubled to NIS 9.5 million, and net profit rose to NIS 6.8 million from NIS 3.7 million.

Those numbers explain why Gad sees the transaction as a fast-entry platform. Instead of building a plant, development capabilities, production lines, people, and category know-how from scratch in a field different from its core dairy franchise, it is buying a business already inside the market. Gad's own strategy section shows this is not a side move: the company says explicitly that the Gad brand on its own does not fit the protein, vegan, and dairy-substitute categories, so it built a dedicated strategy that includes both the Feel Gad sub-brand, planned for launch in the second half of 2026, and the acquisition of control in Weiler.

That matters. Weiler is not supposed to be just an outside supplier making a few products for Gad. It is supposed to be the operating and development layer that lets Gad shorten years of organic build-out.

But that is where the other side enters. The filing states explicitly that the bulk of Weiler's dairy-substitute activity is manufacturing Alpro products for Strauss, and that this activity is expected to end over the coming year as Strauss completes its own plant and shifts to self-production. That is precisely the field Gad wants to use as a growth engine. So Weiler's 2024 numbers are not a clean base year for Gad's plant-based expansion. A piece of that line is already running backward.

This is easy to miss on a superficial read. It is tempting to look at the 21% dairy-substitutes mix and say: great, there is the proven plant-based engine. The filing itself does not support that conclusion. It supports a more complicated one: there is a proven platform here, but the revenue stream closest to Gad's new thesis is also the one already facing runoff.

The Price Tag Does Not Look Aggressive, But It Buys A Transition Period Too

At an enterprise value of NIS 95 million, Weiler is priced at roughly 8.2 times 2024 EBITDA, or around 7.5 times 2024 adjusted EBITDA. That does not look stretched for a company that grew in 2024, operates in the category Gad wants to enter, and brings both capacity and know-how. The fact that NIS 46 million of the IPO proceeds had already been earmarked for completing the Weiler deal also reduces the fear that the acquisition suddenly appears as an unplanned funding hole.

But the filing injects caution here too. As of the report date, Gad still did not have Weiler's audited 2025 financials. So the deal was not signed on the basis of a final, fully visible position. It was signed on the basis of 2024, on EBITDA targets for 2025 and 2026, and on a mechanism meant to share transition risk between seller and buyer.

That chart captures the heart of the economics. The 2025 EBITDA target stands about NIS 1.9 million above the 2024 actual level, and the 2026 target adds another NIS 1.0 million. So the deal is not only underwriting maintenance. It is underwriting improvement. That still sounds reasonable on paper, but it has to be read against the same period in which Weiler is also expected to lose most of its Strauss-linked Alpro volume.

Yes, there is also a synergy layer. Gad expects NIS 2 million to NIS 4 million of synergies, with most of that coming from moving distribution from Strauss's distribution system into Gad's own system, plus savings in finance, business development, and product development. But here too the company writes that those estimates may fail to materialize or may change materially, in part because of facts tied to Weiler's current distribution model that are not fully known to Gad.

So both the main synergy and the main revenue hole sit around the same relationship: Strauss. This is a deal in which the same thread can generate savings and erosion at the same time, depending on how the handoff actually unfolds.

The Downside Protection Helps, But It Is Not Immediate Cash Protection

At first glance the price-adjustment mechanism looks like a comfortable safety net for Gad. If Weiler's EBITDA for 2025 or 2026 turns out to be lower by more than NIS 0.5 million than the relevant annual target, the sellers are supposed to return to Gad an amount equal to the shortfall, multiplied by 7, multiplied by 51%.

But the key is in the last part of the clause. That repayment is not described as cash already locked away, and not as money sitting in escrow. It is supposed to come back to Gad out of the first net dividends that flow to the sellers from Weiler. That is a critical distinction. Gad obtained economic downside sharing, but not immediate cash-on-cash protection.

The practical implication is clear: if performance disappoints there is a mechanism that lowers the effective price. But that mechanism depends on dividends flowing from the subsidiary to the sellers. That is not the same thing as an immediate purchase-price cut on closing.

There is another subtle point. The 2026 target is not fully static either. If Weiler starts receiving distribution services from Gad during 2026, the agreement says that the 2026 target will be adjusted under a predefined mechanism. In other words, even the reference point itself can move once the integration starts.

So the right way to read this protection is as reduced blindness, not as erased risk. Gad did not buy a black box, but it did buy an asset going through operating and commercial change, where the compensation for underperformance is neither immediate nor complete.

The Second Stage Is Already Written Into The Deal

One of the most important points sits after the closing of the initial 51% purchase. Gad holds a call option to buy the remaining stake at 7.5 times EBITDA, net of financial debt and adjusted for normalized working capital, during windows that open after approval of the 2027 and 2028 financial statements. The sellers hold a put option at 6 times EBITDA, under the same principles, in windows that begin immediately after each Gad call window ends.

That structure says two things at once. If Weiler performs well, Gad has a clear path to move from 51% to full ownership at a known multiple. But if Gad prefers to wait, or if the business works less well than planned, the sellers still retain the right to force a sale at 6 times EBITDA.

That is exactly what separates a platform acquisition from a free option. Gad does not get a trial period without future obligations. It gets control now, but with a future path that can still require it to allocate more capital if the business does not resolve itself by 2028 and 2029.

The economic implication is straightforward: even if the initial price looks reasonable, part of the real question has simply moved forward in time. The market should ask not only whether the first NIS 46 million is fair, but whether the remaining 49% can eventually become value accretive rather than another cash obligation.

Where The Revenue Hole Sits, And How Gad Is Trying To Fill It

This is where the strategy layer becomes important. Gad's strategy section does not frame Weiler as a standalone transaction, but as part of a broader move into functional, protein-enriched, and plant-based categories. The company says explicitly that the Gad brand on its own does not fit those categories, which is why it is building the Feel Gad sub-brand alongside the Weiler acquisition. In addition, in August 2025 Gad signed a supply agreement under which Weiler will produce and pack plant-based dairy products for Gad under Gad's own brand, with branding, marketing, and distribution handled by Gad.

So there is a replacement route. Gad is not waiting for the closing to decide what to do with the line. It is already building brand, sales funnel, and distribution around it. The problem is that the filing does not present that agreement as a proven engine that already closes the gap. Quite the opposite: in the Weiler description, the additional agreement with Gad is described as non-material in scope.

That is exactly where the 2026 to 2027 test sits. For Weiler to become a growth engine rather than a transition deal, Gad needs to replace the falling Strauss-linked activity with new demand under a new brand, through a new channel architecture, in a category that the company itself says its legacy brand does not naturally fit.

That is not an argument against the acquisition. It is an argument against reading it too comfortably. Gad is buying speed, not certainty. It is buying an operating shortcut, not locked revenue. That is why the right framework for Weiler is a proof year inside Gad's larger proof year.

Bottom Line

Weiler looks like the right strategic deal for Gad, but not a clean one. The initial price does not look excessive, the company is buying a profitable platform with underused capacity, and the price-adjustment mechanism plus the call and put structure show that both sides understand this is a transition asset, not a sealed box.

But that is exactly why Weiler's 2024 numbers should not be read as a stable revenue base. Most of the dairy-substitute activity leans on Alpro for Strauss, and that activity is expected to run off. So the economics of the deal will not be decided only by whether Gad closes it. They will be decided by whether Gad can refill that plant-based line fast enough through its own brand, distribution, and product strategy.

Put more sharply, Gad is not buying only a growth engine here. It is also buying the revenue hole that has to be filled for that engine to work.